In a recently published retrospective study with comparison of IL-1 inhibition (anakinra) and IL-6 inhibition (tocilizumab or sarilumab) strategies, IL-1 inhibition but not IL-6 inhibition was reported to reduce mortality, respiratory insufficiency, and hyperinflammation significantly in hospitalized COVID-19 patients [20]. This evidence concerns the gene IL1A and COVID-19.